AHA Hypertension 2025 Poster: Efficacy and Safety of Lorundrostat in Hypertension Patients With High Unmet Medical Need: Subgroup Analyses of the Launch-HTN Trial in Uncontrolled and Treatment-Resistant Hypertension
Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension
Phase 3 Efficacy and Safety of a Novel Aldosterone Synthase Inhibitor in Patients with Uncontrolled and Treatment-Resistant Hypertension: Launch-HTN Study
Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension
Advance-HTN 2025 Presentation: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension
ACCP 2024 Poster: Lorundrostat Concentration-QTc Results From the First-in-Human Study in Healthy Participants Demonstrate Lack of Relevant Effect and Replaces the Thorough QT Study
First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor
AHA Scientific Sessions 2023 Poster: Lorundrostat for Treatment of Obesity-Related, Aldosterone-Dependent Hypertension
– An Endotype-Specific, Targeted Approach to the Treatment of Uncontrolled Hypertension
ASN Kidney Week 2023 Poster: Identification of a Hypertensive Endotype with a Median Treatment Effect of -32 mmHg in Response to the Novel Aldosterone Synthase Inhibitor Lorundrostat
AHA Hypertension 2023 Presentation: Target-HTN Trial on the Safety and Efficacy of Lorundrostat (MLS-101) in Patients With Uncontrolled Hypertension
